Polymorphic forms of Cyclo (-His-Pro) and methods of use to treat kidney disease
The present disclosure relates to synthesis and characterization of novel polymorphic forms of Cyclo (-His-Pro) (“CHP”).
1. A method of treating a kidney disease in a subject in need thereof, comprising administering an effective amount of a composition comprising a cyclo(-His-Pro) hydrate compound of the following formula as an active ingredient, to the subject,
wherein the cyclo(-His-Pro) hydrate compound is characterized by an X-ray powder diffraction (XRPD) diffractogram comprising peaks at 2θ values of 13.7°±0.2°, 17°±0.2°, and 27.3°±0.2°.
2. The method of claim 1 , wherein the kidney disease is acute kidney injury (AKI), chronic kidney disease (CKD), or kidney fibrosis.
3. The method of claim 1 , wherein the XRPD diffractrogram further comprises peak at 2θ value of 10°±0.2°.
4. The method of claim 1 , wherein the cyclo(-His-Pro) hydrate compound has a differential scanning calorimetry (DSC) endotherm onset at about 75° C. to about 100° C.
5. The method of claim 1 , wherein the cyclo(-His-Pro) hydrate compound has a differential scanning calorimetry (DSC) endotherm onset at about 115° C. to about 120° C.
6. The method of claim 1 , wherein the cyclo(-His-Pro) hydrate compound has a purity of at least 90%.
7. The method of claim 1 , wherein the composition further comprises an additional therapeutically active agent, a pharmaceutically acceptable carrier, or a combination thereof.
8. The method of claim 7 , wherein the composition comprises about 1%-(w/w) of the cyclo(-His-Pro) hydrate compound based on the total weight of the composition.
9. The method of claim 8 , wherein the composition comprises about 1% to about 20% (w/w) of cyclo(-His-Pro) hydrate compound.
10. The method of claim 1 , wherein the composition is administered orally, topically, parenterally, intravenously, intradermally, colonically, rectally, intramuscularly, or intraperitoneally.
11. The method of claim 1 , wherein the composition is formulated for parenteral administration by injection or continuous infusion.
12. The method of claim 1 , wherein the composition further comprises a metal or a metal compound wherein the metal is selected from the group consisting of copper, zinc, manganese, iron, cobalt, and chromium.
13. The method of claim 12 , wherein the metal is zinc.
14. The method of claim 12 , wherein the metal or metal compound is zinc element, zinc cation, zinc gluconate, zinc acetate, zinc sulfate, zinc picolinate, zinc orotate, or zinc citrate.
15. The method of claim 1 , wherein the composition is lyophilized.